JP7374496B2 - Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用 - Google Patents

Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用 Download PDF

Info

Publication number
JP7374496B2
JP7374496B2 JP2020520706A JP2020520706A JP7374496B2 JP 7374496 B2 JP7374496 B2 JP 7374496B2 JP 2020520706 A JP2020520706 A JP 2020520706A JP 2020520706 A JP2020520706 A JP 2020520706A JP 7374496 B2 JP7374496 B2 JP 7374496B2
Authority
JP
Japan
Prior art keywords
compound
deuterium
cancer
hydrogen
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020520706A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527166A (ja
Inventor
義漢 王
志強 劉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Targetrx Inc
Original Assignee
Shenzhen Targetrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Targetrx Inc filed Critical Shenzhen Targetrx Inc
Publication of JP2020527166A publication Critical patent/JP2020527166A/ja
Priority to JP2022031100A priority Critical patent/JP2022071077A/ja
Application granted granted Critical
Publication of JP7374496B2 publication Critical patent/JP7374496B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2020520706A 2017-06-26 2018-06-25 Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用 Active JP7374496B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022031100A JP2022071077A (ja) 2017-06-26 2022-03-01 Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710493544.X 2017-06-26
CN201710493544 2017-06-26
PCT/CN2018/092588 WO2019001383A1 (zh) 2017-06-26 2018-06-25 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022031100A Division JP2022071077A (ja) 2017-06-26 2022-03-01 Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用

Publications (2)

Publication Number Publication Date
JP2020527166A JP2020527166A (ja) 2020-09-03
JP7374496B2 true JP7374496B2 (ja) 2023-11-07

Family

ID=63772870

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520706A Active JP7374496B2 (ja) 2017-06-26 2018-06-25 Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用
JP2022031100A Withdrawn JP2022071077A (ja) 2017-06-26 2022-03-01 Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022031100A Withdrawn JP2022071077A (ja) 2017-06-26 2022-03-01 Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用

Country Status (6)

Country Link
US (1) US11718611B2 (https=)
EP (1) EP3626241B1 (https=)
JP (2) JP7374496B2 (https=)
CN (2) CN110759908B (https=)
ES (1) ES3028360T3 (https=)
WO (1) WO2019001383A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111747949B (zh) * 2019-03-29 2022-07-01 首药控股(北京)股份有限公司 Bcl-2选择性抑制剂的制备方法
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
IL296582A (en) 2020-04-15 2022-11-01 Beigene Ltd bcl-2 inhibitor
CN111537654B (zh) * 2020-07-07 2020-11-10 上海亚盛医药科技有限公司 N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法
BR112023000320A2 (pt) * 2020-07-10 2023-01-31 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado de sulfonilbenzamida e seu cojugado, método de preparação do mesmo e seu uso
WO2022161496A1 (en) * 2021-02-01 2022-08-04 Ascentage Pharma (Suzhou) Co., Ltd. Sulfonyl benzamide derivatives as bcl-2 inhibitors
WO2024032776A1 (en) * 2022-08-12 2024-02-15 Fochon Biosciences, Ltd. Compounds as bcl-2 inhibitors
CN115286689B (zh) * 2022-09-29 2023-01-06 上海睿跃生物科技有限公司 靶向降解Bcl-2蛋白的化合物及其应用和药物
CN115872963A (zh) * 2022-12-27 2023-03-31 南京哈柏医药科技有限公司 一种维奈托克中间体的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013527202A (ja) 2010-05-26 2013-06-27 アッヴィ・インコーポレイテッド 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤
JP2013543896A (ja) 2010-11-23 2013-12-09 アッヴィ・インコーポレイテッド 選択的ｂｃｌ−２阻害薬を用いた処置方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010138588A2 (en) 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
US8889675B2 (en) * 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP3481397A1 (en) * 2016-07-06 2019-05-15 Concert Pharmaceuticals Inc. Deuterated venetoclax

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013527202A (ja) 2010-05-26 2013-06-27 アッヴィ・インコーポレイテッド 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤
JP2013543896A (ja) 2010-11-23 2013-12-09 アッヴィ・インコーポレイテッド 選択的ｂｃｌ−２阻害薬を用いた処置方法

Also Published As

Publication number Publication date
CN110759908B (zh) 2021-03-12
ES3028360T3 (en) 2025-06-19
EP3626241A4 (en) 2020-05-27
EP3626241B1 (en) 2025-04-23
WO2019001383A1 (zh) 2019-01-03
US11718611B2 (en) 2023-08-08
JP2020527166A (ja) 2020-09-03
JP2022071077A (ja) 2022-05-13
EP3626241A1 (en) 2020-03-25
CN108658983B (zh) 2019-12-20
CN110759908A (zh) 2020-02-07
CN108658983A (zh) 2018-10-16
US20200216442A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
JP7374496B2 (ja) Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用
TWI804933B (zh) 用作cdk7激酶抑制劑的化合物及其應用
JP7710223B2 (ja) 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
WO2020233641A1 (zh) 用作ret激酶抑制剂的化合物及其应用
TW201620896A (zh) 苯并咪唑衍生物及其醫藥組合物及使用方法
EP4155304B1 (en) Compound used as ret kinase inhibitor and application thereof
JP2023109924A (ja) ジヒドロイミダゾピラジノン化合物、該化合物を含む組成物およびその使用
KR20230074722A (ko) 피라졸 보론산 화합물, 이를 함유하는 약학적 조성물, 및 이의 용도
JP2026502215A (ja) Ｐｒｍｔ５－ｍｔａ阻害剤
CN111518082B (zh) 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
WO2025051211A1 (zh) 用作cdk4激酶抑制剂的化合物及其应用
CN109111439B (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
JP2023036957A (ja) ジアリールピラゾール化合物、該化合物を含む組成物およびその使用
HK40061853B (zh) 用作cdk7激酶抑制剂的化合物及其应用
HK40116388A (zh) 用作cdk7激酶抑制剂的化合物及其应用
CN107235960A (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
WO2024245060A1 (zh) HDAC1-CoREST高选择性抑制剂
WO2024008083A1 (zh) 用作cdk7激酶抑制剂的化合物及其应用
WO2013144971A1 (en) New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them
HK40090211A (en) Compound used as ret kinase inhibitor and application thereof
JP2008120699A (ja) 新規ピリジニウム誘導体および医薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210706

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220301

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220301

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220316

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220322

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220513

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220517

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231018

R150 Certificate of patent or registration of utility model

Ref document number: 7374496

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150